Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CrystalGenomics, Inc.
South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities.
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
- Other Names / Subsidiaries
- CG Pharmaceuticals, Inc.
- Bexpharm Ltd.
- BexpharmKorea Ltd.
- Hwail Pharmaceutical Co., Ltd.
- Palkion, Inc
- CrystalGenomics Inc.